Age of onset, year
|
33.35
|
33.16
|
−0.183
|
4.740
|
0.969
|
Mean BMI
|
23.89
|
24.63
|
0.741
|
1.415
|
0.604
|
Disease duration, months
|
80.40
|
94.17
|
13.77
|
25.81
|
0.589
|
Duration of AZA therapy, months
|
22.10
|
20.50
|
−1.6
|
2.278
|
0.488
|
Mean CSF protein, mg/dl
|
39.82
|
41.43
|
1.613
|
13.275
|
0.904
|
Mean Concentration of CSF IgG, mg/ml
|
0.040
|
0.032
|
−0.008
|
0.014
|
0.577
|
CSF IgG index (n%)
|
0.546
|
0.494
|
−0.519
|
0.039
|
0.199
|
Serum anti-AQP4 antibodies (n%)
|
10 (50%)
|
4 (33.3%)
|
/
|
/
|
0.471
|
Pre-therapy EDSS score
|
5.17
|
5.29
|
/
|
/
|
0.687
|
Post- therapy EDSS score
|
2.43
|
2.83
|
/
|
/
|
0.893
|
Normalized concentration of 6-TGNs
|
1.12
|
0.70
|
−0.418
|
0.09
|
<0.0001*
|
Normalized concentration of 6-MMPNs
|
10.60
|
3.62
|
−6.983
|
2.32
|
0.006*
|